NASDAQ · Biotechnology

Grace Therapeutics, Inc. (GRCE) Stock

$2.02 -2.88% NASDAQ: GRCE Healthcare

Valuation

MetricValue
Price$2.02
Market Cap$32.87M
P/E Ratio-1.64
P/B Ratio0.74
P/S Ratio0.00
EPS (TTM)$-0.95
52-Week High$5.18
52-Week Low$1.79
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-35.78%
ROA-42.84%
ROCE-52.61%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio11.50

Annual Financials (USD)

Metric20222023202420252026
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-71.0M$-17.0M$-24.0M$-11.0M
Net Profit$-12.0M$-57.0M$-17.0M$-14.0M$-8.0M
EPS$-2.02$-7.72$-1.83$-1.13$-0.47
Op Margin—————

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$129.0M$79.0M$73.0M$72.0M$67.0M
Total Liabilities$20.0M$11.0M$12.0M$5.0M$3.0M
Cash$30.0M$28.0M$23.0M$22.0M$17.0M
Borrowings$0$0$0$0$0

Latest News

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update GlobeNewswire · Jun 18, 2026 Sector Update: Health Care Stocks Edge Lower Late Afternoon MT Newswires · Apr 23, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-17.0M$-16.0M$-12.0M$-15.0M$-9.0M
Investing Cash Flow$-4.0M$13.0M$0$0$0
Financing Cash Flow$0$0$0$-1.0M$0
Net Cash Flow$-21.0M$-2.0M$-5.0M$-1.0M$-5.0M
Free Cash Flow$-17.0M$-16.0M$-12.0M$-15.0M$-9.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.77
FCF Yield-30.73%
Quick Ratio11.47
Interest Coverage0.00
Return 1Y-23.35%
Return 3Y-2.20%
Return 5Y-89.81%

Ownership

Insiders Held25.73%
Institutions Held26.46%
Institutions Float Held35.62%
Institutional HolderSharesReport Date
Cerity Partners LLC849,0552026-03-31
Eversept Partners, LP756,6002026-03-31
Nantahala Capital Management, LLC728,2032026-03-31
Bank of America Corporation494,7232026-03-31
Vanguard Capital Management LLC401,6562026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.97 +1.29% 38.93 $5.01T 0.32%
MSFTMicrosoft Corporation $541.15 +1.14% 28.68 $4.02T 0.76%
GOOGLAlphabet Inc. $352.72 +0.30% 16.94 $4.27T 0.26%
AMZNAmazon.com, Inc. $259.53 -1.11% 19.82 $2.79T 0.00%
METAMeta Platforms, Inc. $742.96 +3.38% 27.93 $1.89T 0.28%

About Grace Therapeutics, Inc.

Grace Therapeutics, Inc. is led by CEO Prashant Kohli, employs 4 people, headquartered in US, publicly traded since 2012.

Grace Therapeutics, Inc. (GRCE) stock trades at $2.02 with a market capitalization of $32.87M. The stock is valued at a price-to-earnings (P/E) ratio of -1.64, price-to-book of 0.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.79 and $5.18, and currently trades 61.0% below its 52-week high.

On profitability, Grace Therapeutics, Inc. generates a return on equity (ROE) of -35.78%, return on capital employed of -52.61%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1182.62 +0.28% JNJ Johnson & Johnson $263.73 +0.88% ABBV AbbVie Inc. $281.04 +1.65% MRK Merck & Company, Inc. Common Stock (new) $145.45 -0.10% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.52 -0.21% NVS Novartis AG $143.84 +0.06% AZN AstraZeneca PLC $158.33 -0.55% TMO Thermo Fisher Scientific Inc $662.24 +0.64% AMGN Amgen Inc. $417.57 +0.65% GILD Gilead Sciences, Inc. $150.43 -0.49% ABT Abbott Laboratories $101.82 +2.23% NVO Novo Nordisk A/S $38.58 -0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides